Welcome to our dedicated page for Autonomix Medical news (Ticker: AMIX), a resource for investors and traders seeking the latest updates and insights on Autonomix Medical stock.
Autonomix Medical, Inc. develops precision nerve-targeted medical device technology for diagnosing and treating diseases involving the nervous system. The company’s platform includes a catheter-based microchip sensing array intended to detect and differentiate neural signals and support transvascular approaches to peripheral nerve identification and treatment.
Recurring AMIX news centers on clinical and scientific updates for transvascular radiofrequency energy-based ablation, including pain mitigation research in pancreatic adenocarcinoma and peripheral nerve modulation. Company announcements also cover medical and interventional conference presentations, abstract selections, publication strategy, corporate presentations, and the clinical validation process for its minimally invasive nerve-targeted platform.
Autonomix Medical (NASDAQ: AMIX) reported positive preclinical results showing its proprietary neural sensing platform can detect, localize and confirm changes in renal neural activity in an animal model. The endovascular Autonomix catheter was positioned in renal arteries, where researchers recorded neural signals across multiple anatomical locations and observed consistent activity patterns.
After targeted ablation, the team observed attenuation of previously detected neural signals, indicating the platform may both identify neural targets and assess changes in neural activity following therapy. According to Autonomix Medical, these findings support continued development of physiology-guided renal denervation procedures that provide direct physiological feedback, potentially enabling more precise, patient-specific treatment for conditions such as resistant hypertension. The company plans additional preclinical and future clinical studies to further evaluate neural sensing in renal denervation.
Autonomix Medical (NASDAQ: AMIX) announced the issuance of U.S. Patent No. 12,471,776, titled “ANS Assessment Systems, Kits, and Methods,” which broadens protection for its autonomic nervous system (ANS) assessment technologies. The patent covers systems, devices and methods for monitoring physiologic signals to evaluate sympathetic and parasympathetic nervous system activity using multiple assessment techniques.
According to Autonomix, the intellectual property may support patient selection, procedural guidance, treatment feedback and post-treatment monitoring across a wide range of neuromodulation applications. The patented systems use advanced imaging, sensors and algorithms to analyze ANS activity and are aimed at precision-based diagnosis and treatment of diseases involving the peripheral nervous system, further expanding the company’s neuromodulation-focused IP portfolio.
Autonomix Medical (NASDAQ: AMIX) announced issuance of U.S. Patent No. 12,611,134 for “Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder,” expanding its neural sensing and therapeutic platform into urology. The patent covers a catheter-based, minimally invasive system for bladder-wall nerve mapping and targeted therapies, including radiofrequency, thermal, ultrasonic energy and localized drug delivery. It also includes an implantable device for long-term monitoring and potential sustained local drug release. According to Autonomix Medical, this adds to a portfolio of 112 issued or pending patents worldwide, with protections extending into the late 2030s, supporting multi-organ, organ-specific applications from a single core technology.
Autonomix Medical (NASDAQ: AMIX) entered a warrant inducement agreement with an existing investor for the immediate cash exercise of November 19, 2025 warrants covering 428,731 shares of common stock at an amended exercise price of $6.00 per share, expected to generate approximately $2.6 million in gross proceeds before fees.
In return, Autonomix Medical will issue the investor unregistered Series D-1 and Series D-2 warrants, each for 428,731 shares, at a $5.75 exercise price, exercisable immediately and expiring five and a half years after issuance. The closing is expected around July 15, 2026, and the company plans to register the resale of shares underlying the new warrants.
Autonomix Medical (NASDAQ: AMIX) announced the grant of Canadian Patent No. 3,158,197, "Endoscopic Sympathectomy Systems and Methods," strengthening its global intellectual property portfolio for nerve-targeted therapies and denervation applications. The company now holds 112 issued or pending patent applications worldwide, with coverage in the United States, Europe, Canada and other key jurisdictions.
The patent protects systems and methods for real-time nerve sensing, mapping, physiological monitoring and closed-loop neuromodulation using minimally invasive, sensor-enabled tools and implantable devices. These technologies are intended to enhance targeting of autonomic nerves involved in conditions such as hypertension, chronic heart failure, chronic renal failure and metabolic disorders, with expirations extending into the late 2030s.
Autonomix Medical (NASDAQ: AMIX) announced a proprietary standalone neural sensing platform based on its core technology, with preclinical evidence of detecting renal nerve activity and real-time changes after intervention.
The platform initially targets renal denervation for resistant hypertension and is designed for broader cardiovascular and autonomic nerve applications.
Autonomix (NASDAQ: AMIX) approved a 1-for-21 reverse stock split of its common stock, effective 12:01 a.m. ET on June 24, 2026. Shares will continue trading on Nasdaq under AMIX with new CUSIP 05330T304.
The split reduces outstanding shares from about 11.4 million to about 543,000, with par value unchanged at $0.001. Fractional shares will not be issued; holders will receive cash instead. Authorized shares remain at 500 million, and equity plan reserves will be proportionately reduced.
Autonomix Medical (NASDAQ: AMIX) released a new CEO Corner segment featuring President and CEO Brad Hauser. The update highlights growing global scientific and clinical recognition for its nerve-sensing and transvascular denervation platform, including 13 abstract acceptances, nine podium and four poster presentations, across leading conferences.
The technology, honored with a top Cardiovascular Innovation Award at CRT, is presented as having potential to transform treatment of complex conditions such as pancreatic cancer pain and to support physician adoption, future clinical trials, partnerships, reimbursement discussions, and a planned U.S. clinical study.
Autonomix Medical (NASDAQ: AMIX) announced its participation in a Virtual Investor “What This Means” segment featuring Dr. Toufic Kachaamy, Chief of Medicine at City of Hope in Phoenix.
The discussion covered clinical data presented at the Society of Surgical Oncology meeting, focusing on visceral cancer pain treatment, pancreatic cancer feasibility, and broader peripheral nervous system platform potential.
Autonomix Medical (NASDAQ: AMIX) received U.S. Patent No. 12,544,131 covering systems for monitoring and treating tissues within and through a lumen wall. The patent supports minimally invasive transvascular access to nerves and tissues, with real-time electrophysiological feedback for procedural validation and adaptive neuromodulation.
The patent adds multi-site sensing, closed-loop control, and broad signal and therapy coverage, enhancing Autonomix’s global IP portfolio, which spans nerve mapping, signal processing, and controlled micro-ablation across multiple organ systems, with expirations extending into the late 2030s.